N6022 (1208315-24-5) is a potent and reversible inhibitor of S-nitrosoglutathione reductase (GSNOR) – IC50?= 20 nM1, 8 nM2. It demonstrated significant efficacy in mouse models of ovalbumin-induced asthma, chronic obstructive pulmonary disease, and irritable bowel syndrome. N6022 was able to attenuate experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis)?via?selective inhibition of pro-inflammatory CD4+?cells (TH1/TH17) while upregulating anti-inflammatory subsets of CD4+?cells (TH2/Treg) without causing lymphopenia.3
N6022 is a tight-binding, specific, and fully reversible inhibitor of S-nitrosoglutathione reductase.
1) Sun?et al.?(2011),?Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases; ACS Med. Chem. Lett.?2?402
2) Green?et al.?(2012),?Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase; Biochemistry?51?2157
3) Saxena?et al.?(20198),?S-Nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis; Free Radic. Biol. Med.?121?57
